News
Insilico Develops The World’s First Fully AI-Generated Drug
The Abu Dhabi-based company hopes to treat idiopathic pulmonary fibrosis, and has 30 more drugs in the pipeline.
In a busy biotech hub in Abu Dhabi’s Masdar City, Insilico Medicine is pushing the frontiers of science. Under the watchful eye of Latvian-born CEO Dr Alex Zhavoronkov, the company has developed an AI-generated drug to treat idiopathic pulmonary fibrosis (IPF) — a deadly disease of the lungs.
“This AI drug is a major milestone for us and the industry as a whole,” Dr. Zhavoronkov explains. “We can use AI to create lifesaving treatments for new diseases using approaches we haven’t yet considered and do so much more rapidly and efficiently”.
Idiopathic pulmonary fibrosis is characterized by scarring of the lungs and has no known cure. Insilico’s AI drug aims to halt or even reverse the progression of IPF and is currently undergoing Phase 2 clinical trials in the US and China. The success of these trials will pave the way for more in-depth testing, bringing the drug closer to mass market approval.
Insilico’s groundbreaking research was recently published in Nature Biotechnology. It highlights how the company’s AI platform, Pharma.AI, is connecting the dots between fibrosis and aging to drive forward the discovery of a cure.
IPF treatment is just the beginning for Insilico. The company already has a roadmap consisting of over thirty AI-designed drugs, with seven already in clinical patient trials. These include treatments for inflammatory bowel disease, immuno-oncology targets, and even drugs developed using a method that targets a protein in cancers that can kill them without harming healthy cells.
Also Read: Personalized Supplement Company Bioniq Raises $15M In Funds
Dr Zhavoronkov’s ultimate goal is to leverage AI to unravel the complex processes involved in aging. “Our number one priority is to teach AI to understand the basic biology of aging, and I think we’ve succeeded in that process. Now, we need to demonstrate that we can utilize this understanding to cure diseases,” he says.
Insilico Medicine’s AI-driven drugs showcase the massive untapped potential of artificial intelligence in all aspects of healthcare. As the company continues to innovate, its work brings hope to patients around the world and demonstrates that the future of medicine is promising, thanks to the application of the latest technological breakthroughs.
News
NEOPAY Wants To Follow Merchants Across Channels And Borders
A controlling 65% stake in noon payments would give NEOPAY access to marketplace sellers, online merchants and the payment flows they generate.
It’s been a long time since checkouts were single defined places. A merchant might take payments at a physical register, on its own website and through an online marketplace, sometimes in more than one country. NEOPAY wants to follow those transactions wherever they happen.
The UAE payments company has entered into an agreement to acquire a 65% controlling stake in noon payments. NEOPAY already runs the acquiring infrastructure that lets merchants accept card payments, along with omnichannel acceptance and a merchant services platform. This new deal would add noon payments’ embedded payments platform, e-commerce gateway and merchant network across the UAE, Saudi Arabia and Egypt. That would considerably expand both NEOPAY’s digital commerce capabilities and its regional reach.
For merchants, the attraction is a single provider for online and in-store payments, plus faster settlements, data and analytics, and value-added financial services.
“Payments should be simple, reliable, and built for the markets they serve,” said Faraz Khalid, CEO of noon. His counterpart at NEOPAY, Vibhor Mundhada, added: “We have built a strong payments business in the UAE, and our ambition is now to take that capability across the region”. The acquisition, Mundhada added, would “expand our footprint into Saudi Arabia and Egypt” while reinforcing NEOPAY’s position at home.
Also Read: In Kuwait, Your Surgeon Might Be Operating From Another Country
NEOPAY is also keen to point out potential payment volume increases. The company says noon payments’ integrations with marketplace sellers and online merchants create high transaction density in some of the region’s fastest-growing digital commerce segments. It also believes control of the business would give it access to those merchant relationships and payment flows, and speed up the rollout of alternative payment methods and installment options.
The combined roadmap targets faster merchant onboarding, better payment performance, tighter fraud controls and embedded financial services. The deal could also strengthen cross-border payments and settlement along key regional commerce corridors.
NEOPAY Wants To Follow Merchants Across Channels And Borders
RØDE’s Low-Profile Studio Arm Is Designed To Stay Out Of Shot
Microsoft Plans $10 Billion-Plus Gulf Expansion Despite Iran Conflict
In Kuwait, Your Surgeon Might Be Operating From Another Country
Qatar Folds 45 State Companies Into A Single Investment Platform
Trip.com Is Betting An AI Agent Will Book Your Next Vacation
Apple’s First Folding iPhone Arrives Late To A Shrinking Market
Egypt’s Mobile Wallets Are Booming, But Cash Still Has Power
Musk’s Boring Company Wants To Dig 150 KM Of Tunnel Under The UAE
OKX Bets Streaming Perks Can Take Crypto Mainstream Across MENA
-
News3 weeks agoTrip.com Is Betting An AI Agent Will Book Your Next Vacation
-
News3 weeks agoEgypt’s Mobile Wallets Are Booming, But Cash Still Has Power
-
News3 weeks agoMusk’s Boring Company Wants To Dig 150 KM Of Tunnel Under The UAE
-
News3 weeks agoOKX Bets Streaming Perks Can Take Crypto Mainstream Across MENA